4baseCare Philippines’ Post

𝐓𝐚𝐫𝐆𝐓 𝐅𝐢𝐫𝐬𝐭 𝐢𝐬 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐚𝐧𝐝 𝐚𝐟𝐟𝐨𝐫𝐝𝐚𝐛𝐥𝐞 𝐩𝐚𝐧-𝐬𝐨𝐥𝐢𝐝 𝐜𝐚𝐧𝐜𝐞𝐫 𝐠𝐞𝐧𝐞 𝐩𝐚𝐧𝐞𝐥𝐬 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞, 𝐞𝐧𝐜𝐨𝐦𝐩𝐚𝐬𝐬𝐢𝐧𝐠 𝟕𝟐 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐜𝐨𝐦𝐦𝐨𝐧𝐥𝐲 𝐦𝐮𝐭𝐚𝐭𝐞𝐝 𝐜𝐚𝐧𝐜𝐞𝐫-𝐚𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐞𝐝 𝐠𝐞𝐧𝐞𝐬 𝐰𝐢𝐭𝐡 𝐚 𝐡𝐢𝐠𝐡 𝐥𝐞𝐯𝐞𝐥 𝐨𝐟 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞 𝐟𝐨𝐫 𝐛𝐨𝐭𝐡 𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐚𝐧𝐝 𝐩𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐚𝐭𝐢𝐨𝐧. ⭐️𝐓𝐚𝐫𝐆𝐓 𝐅𝐢𝐫𝐬𝐭 is considered a breakthrough test because it has helped 4baseCare identify multinucleotide Variants in 𝐊𝐑𝐀𝐒. 🧪🧬This test covers the well-known 𝐠𝐞𝐧𝐨𝐦𝐢𝐜 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 for which #NCCN and #FDA-approved therapy options are available to treat solid cancers. It has been developed to make cancer #biomarker testing affordable and accessible for every #cancer patient. #Biomarkers #TarGTFirst #FDA #GenomicTesting #CancerResearch #CancerCare #PrecisionOncology Hitesh Goswami

Understand Your Patient's Risk of Developing Breast and Ovarian Cancer as a Second Primary with the Everything Genetic 12 Gene Breast Cancer Panel. The test looks at all the important genes associated with inherited breast and ovarian cancer, particularly BRCA1, BRCA2, and 10 other important genes. A woman with a pathogenic variant in the gene BRCA1, for example, has a 50-80% risk of developing breast cancer, while the average woman has a risk of only 10%. Understanding that risk will allow for tailored screening, early detection, and better prevention of cancer. Find out more: https://buff.ly/3xbhT8d Our Medical Director, Dr James Mackay talks about who this panel is suitable for in the short video below ⬇️ #BreastCancer #BreastCancerTest #GeneticTestForBreastCancer #12GenePanel #UKGeneticTest #GeneticTesting #NGSTesting #GeneticTest #BreastCancerRiskTest #BreastCancerRisk #CancerPrevention #CancerTreatment #CancerDiagnosis

September 2024 marks the Blood Cancer Awareness Month. As professionals in the health care system for tumor diagnostics, we are aware of the importance of having reliable diagnostic tools. Blood cancer is diagnosed in over 1 million patients every year and describes more than 100 different types of cancer that affect the production and function of blood cells.  With increasing knowledge of different tumor classes in blood cancer comes the demand for more specified molecular diagnostic methods. Many subtypes of blood cancer can be diagnosed by testing for certain genetic alterations. Fluorescence in situ hybridization (FISH) is one of the most reliable methods to detect such gene alterations allowing for tumor classification and individual therapy decisions.     ZytoVision’s FISH portfolio includes over 60 probes that are routinely used to aid blood cancer diagnostics all over the world.     #bloodcancer #bloodcancerawareness #ThisIsBloodCancer

Understanding genetic factors in hereditary cancer helps tailor proactive management and preventive measures, aiming for the best possible patient outcomes and support. Some cancers have a stronger genetic predisposition, with hereditary syndromes making up around 3-20% of all cancer cases. Unilabs provides oncogenetic consultations which can unlock possible risk-reducing interventions and provide informed clinical decisions for the patient. Developments in next-generation sequencing allow us to quickly analyse multiple genes at once, helping identify harmful gene changes linked to hereditary cancers. Additionally, new treatments like PARP inhibitors and checkpoint inhibitors show promise for cancers with specific genetic mutations.  Learn more from Unilabs' Oncogenetics specialist Dr Zuzana Mazerikova.  https://lnkd.in/eN_vp_64 #Genetics #Oncology #Cancer #Healthcare 

A recent study by Le Compte et al. illustrates how RNA-Seq can be used to characterize organoids as models for cancer treatment and identify intra-patient response heterogeneity in pancreatic ductal adenocarcinoma, one of the most lethal cancers. RNA-Seq provides a powerful tool that can be used to study gene expression in organoids, and allows identification of genes that are associated with #cancer progression and #drug resistance to develop new therapies for pancreatic cancer in the future. Read the full article: https://lnkd.in/dKCtY5XT 🚀 Ready to start your #RNAseq experiments for #organoids? ⭐ Lexogen is your trusted #NGS partner for drug discovery workflows and cancer models. 💰 Save up to 50% with limited service offer until the end of 2024! Go here for all details: https://lnkd.in/gtrYYC8D #DrugDiscovery #GeneExpression

✨ Exciting Update! ✨ KRAS Gene Mutation Testing is now available in-house at LEO Healthcare. Faster results, greater precision, and enhanced cancer care—all under one roof! Proud to see us take another step toward advancing diagnostics for better patient outcomes. 💡 #KRAS #InHouseTesting #PrecisionMedicine #HealthcareInnovation #leohealthcare #servicewithprofessionandpassion #em_onthego

KRAS Gene Mutation test by in-house PCR Technology @Leo Healthcare Advanced Diagnostic Laboratory Some Clinical Significance 1) Ca Lungs - Predicting therapy resistance for Anti EGFR Therapy 2) Targeted Therapy - Kras G12C mutations in Ca Lungs 3) Prognostic Marker - poor Prognostic in Pancreatic Adenocarcinoma & mCRC.

Understanding CHEK2: A Key Gene in Cancer Susceptibility 🔬 CHEK2 heterozygotes (one loss-of-function variant) face increased risks for cancers, particularly prostate cancer, and potentially others like urinary tract, lymphoid, and endocrine cancers 🧬 This month’s suggested read uses an unbiased genomic ascertainment method, revealing subtler or late-onset cancer risks without the bias of family history-based selection 🦠 In support of Movember, 4bases offers the HEVA pro kit for detecting CHEK2 and other cancer-related gene variants, aiding early diagnosis and personalised care Read more here 👉 https://lnkd.in/dB7n_MnM #Movember #MensHealth #CancerRisk 

Faster Results for Clinicians Treating Breast Cancer Patients Waiting for test results can be a big setback in clinical cancer care, especially if preventative treatment may be urgently required. The Everything Genetic 12 Gene Breast Cancer Panel is delivered from a UK laboratory, allowing you to receive clinically actionable results in just 2–3 weeks. This allows you to quickly determine best next steps for treatments and implement the right preventative care for your patients. By identifying the disease-causing variant, the 12 Gene Breast Cancer Panel can also guide testing and management of at-risk relatives. Find out more: https://buff.ly/3xbhT8d Listen what our Medical Director, Dr James Mackay, has to say about this test in the video below ⬇️ #BreastCancer #BreastCancerTest #GeneticTestForBreastCancer #12GenePanel #UKGeneticTest #GeneticTesting #NGSTesting #GeneticTest #BreastCancerRiskTest #BreastCancerRisk #CancerPrevention #CancerTreatment #CancerDiagnosis

In recognition of Sarcoma Awareness Month, did you know that inherited cancer gene mutations in TP53, RB1, NF1, APC, KIT, and PDGFR can raise the risk for certain sarcomas? In fact, one in ten people with osteosarcoma have an inherited cancer risk gene mutation. If you are a sarcoma patient, you may want to consider genetic testing. We ask that you also consider joining our CAUSAL study through which we trying to learn more about sarcoma patients. No travel to our center is needed, and everything can be done online. Participating in this study involves taking surveys, monitoring your physical activity with a free Fitbit, free genetic testing for inherited cancer, and free tumor testing. Your participation could help develop new ways to improve cancer treatment and quality of life as well as to learn more about sarcoma causes and prevention.   To learn more about participating, please visit https://lnkd.in/eXEPh7JB   #ICARE #InheritedCancer #HereditaryCancer #Cancer #Sarcoma #CancerResearch #CAUSAL #GeneticTesting #TP53 #RB1 #NF1 #APC #KIT #PDGFR #CancerGenomics #CancerRisks #CancerPrevention American Society of Clinical Oncology (ASCO) American Cancer Society National Cancer Institute (NCI) Vanderbilt Health VANDERBILT-INGRAM CANCER CENTER AT GREEN HILLS